Vaccines 2013, 1(2), 174-203; doi:10.3390/vaccines1020174
Review

Tumor-Associated Glycans and Immune Surveillance

1 Winthrop P. Rockefeller Cancer Institute and Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA 2 Stephan Angeloff Institute of Microbiology, BAS, Sofia 1113, Bulgaria
* Author to whom correspondence should be addressed.
Received: 18 April 2013; in revised form: 18 April 2013 / Accepted: 6 June 2013 / Published: 17 June 2013
(This article belongs to the Special Issue Feature Papers)
PDF Full-text Download PDF Full-Text [680 KB, uploaded 17 June 2013 12:24 CEST]
Abstract: Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in clinical applications. T-cells, being a part of the adaptive immune response, are the most popular component of the immune system considered for targeting tumor cells. However, for TACAs, T-cells take a back seat to antibodies and natural killer cells as first-line innate defense mechanisms. Here, we briefly highlight the rationale associated with the relative importance of the immune surveillance machinery that might be applicable for developing therapeutics.
Keywords: monoclonal antibodies; immunotherapy; cancer; mimics; vaccine; TACA; glycans; tumor; carbohydrate

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Monzavi-Karbassi, B.; Pashov, A.; Kieber-Emmons, T. Tumor-Associated Glycans and Immune Surveillance. Vaccines 2013, 1, 174-203.

AMA Style

Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. Tumor-Associated Glycans and Immune Surveillance. Vaccines. 2013; 1(2):174-203.

Chicago/Turabian Style

Monzavi-Karbassi, Behjatolah; Pashov, Anastas; Kieber-Emmons, Thomas. 2013. "Tumor-Associated Glycans and Immune Surveillance." Vaccines 1, no. 2: 174-203.

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert